Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 15/20 | 0.72 |
| ▸ | THRA | P10827 | 13/20 | 0.72 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.72 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.62 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | ASPH | Q12797 | 1/20 | 0.59 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522269 | 0.91 | THRA (0.70) | THRBTHRAEGLN1BBOX1FTO | |
| SCHEMBL522745 | 0.91 | THRA (0.70) | THRBTHRAEGLN1BBOX1FTO | |
| SCHEMBL523344 | 0.88 | THRA (0.76) | THRBTHRAEGLN1BBOX1FTO | |
| SCHEMBL31028941 | 0.88 | THRA (0.76) | THRBTHRAEGLN1BBOX1FTO | |
| SCHEMBL522867 | 0.87 | THRA (0.64) | THRBTHRAEGLN1BBOX1FTO | |
| SCHEMBL522268 | 0.86 | THRA (0.72) | THRBTHRAEGLN1BBOX1FTO | |
| SCHEMBL1509116 | 0.86 | THRA (0.75) | THRBTHRAEGLN1BBOX1FTO | |
| SCHEMBL30004356 | 0.86 | THRA (0.75) | THRBTHRAEGLN1BBOX1FTO | |
| SCHEMBL522828 | 0.84 | THRA (0.84) | THRBTHRAEGLN1BBOX1FTO | |
| SCHEMBL522940 | 0.84 | THRA (1.00) | THRBTHRAEGLN1BBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258660-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN, INC. (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258660-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | HIF1A, HIF1AN, EGLN2 | THRB 2049/4885THRA 1730/4885EGLN1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.